文献速递甲状腺疾病

Graves病中功能性促甲状腺激素受体抗体的前瞻性试验

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项前瞻性2年试验在连续100例未治疗Graves病甲亢患者中评估TSAb和TBAb的临床效用与预测价值,发现TSAb水平反映疾病严重程度,MMI治疗中TSAb升高提示疾病活动持续,TSAb稀释分析有额外预测价值。

要点

  • 44例对MMI有应答,其中43%有Graves眼病;56例无应答,其中66%有Graves眼病(P < 0.01)。
  • 应答者治疗中TSAb显著下降(P < 0.001),无应答者TSAb升高(P < 0.01)。
  • 72周随访期内所有无应答和/或复发者在第24周均为TSAb阳性。

核心结论

  • 血清TSAb水平反映Graves病严重程度,其在MMI治疗期间升高是疾病活动持续的标志。
  • TSAb稀释分析具有额外预测价值。

研究设计与样本

  • 前瞻性2年试验,在学术三级转诊中心连续纳入100例未治疗的Graves病甲亢患者。
  • TSAb以样本与参考比值百分比(SRR)报告(截止值SRR < 140%),阻断活性定义为相对于牛促甲状腺激素单独诱导的荧光素酶表达抑制百分比(截止值> 40%抑制)。
  • 主要结局指标为对24周甲巯咪唑(MMI)治疗有无应答,定义为第24周生化甲状腺功能正常 versus 持续甲亢,和/或第36、48、96周复发。

主要发现

  • 44例患者对MMI有应答,其中43%有Graves眼病;56例无应答,其中66%有Graves眼病(P < 0.01)。
  • 基线时,未稀释血清TSAb可区分单纯甲状腺Graves病与Graves病+Graves眼病(P < 0.001),而甲状腺结合抑制免疫球蛋白(TBII)不能区分。
  • 基线时,应答者与无应答者稀释TSAb滴度存在显著差异(P < 0.001)。
  • 治疗期间,应答者血清TSAb水平显著下降(P < 0.001),而无应答者升高(P < 0.01);相反,无应答者TBII显著下降(P = 0.002)。
  • 72周随访期内所有无应答和/或复发者在第24周均为TSAb阳性;8例患者在治疗和/或随访期间出现从TSAb向TBAb的转换并导致缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). OBJECTIVE: To evaluate the clinical utility and predictive value of TSAb/TBAb. DESIGN: Prospective 2-year trial. SETTING: Academic tertiary referral center. PATIENTS: One hundred consecutive, untreated, hyperthyroid GD patients. METHODS: TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition). MAIN OUTCOME MEASURES: Response versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96. RESULTS: Forty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission. CONCLUSIONS: Serum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kahaly GJ, Diana T, Kanitz M, et al. Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease. J Clin Endocrinol Metab. 2020. PMID: 31865369. doi:10.1210/clinem/dgz292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。